108 related articles for article (PubMed ID: 9639444)
1. Effects of fenretinide (4-HPR) on dark adaptation.
Caruso RC; Zujewski J; Iwata F; Podgor MJ; Conley BA; Ayres LM; Kaiser-Kupfer MI
Arch Ophthalmol; 1998 Jun; 116(6):759-63. PubMed ID: 9639444
[TBL] [Abstract][Full Text] [Related]
2. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface.
Decensi A; Torrisi R; Polizzi A; Gesi R; Brezzo V; Rolando M; Rondanina G; Orengo MA; Formelli F; Costa A
J Natl Cancer Inst; 1994 Jan; 86(2):105-10. PubMed ID: 8271292
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of fenretinide on retinal function.
Decensi A; Fontana V; Fioretto M; Rondanina G; Torrisi R; Orengo MA; Costa A
Eur J Cancer; 1997 Jan; 33(1):80-4. PubMed ID: 9071904
[TBL] [Abstract][Full Text] [Related]
5. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
6. Total rod ERG suppression with high dose compassionate Fenretinide usage.
Marmor MF; Jain A; Moshfeghi D
Doc Ophthalmol; 2008 Nov; 117(3):257-61. PubMed ID: 18523815
[TBL] [Abstract][Full Text] [Related]
7. Abnormal retinal function associated with fenretinide, a synthetic retinoid.
Kaiser-Kupfer MI; Peck GL; Caruso RC; Jaffe MJ; DiGiovanna JJ; Gross EG
Arch Ophthalmol; 1986 Jan; 104(1):69-70. PubMed ID: 2935125
[TBL] [Abstract][Full Text] [Related]
8. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
9. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
Baglietto L; Torrisi R; Arena G; Tosetti F; Gonzaga AG; Pasquetti W; Robertson C; Decensi A
Cancer Detect Prev; 2000; 24(4):369-75. PubMed ID: 11059568
[TBL] [Abstract][Full Text] [Related]
10. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
11. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration.
Thaller C; Shalev M; Frolov A; Eichele G; Thompson TC; Williams RH; Dillioglugil O; Kadmon D
J Clin Oncol; 2000 Nov; 18(22):3804-8. PubMed ID: 11078493
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability.
Mariani L; Formelli F; De Palo G; Manzari A; Camerini T; Campa T; Di Mauro MG; Crippa A; Delle Grottaglie M; Del Vecchio M; Marubini E; Costa A; Veronesi U
Tumori; 1996; 82(5):444-9. PubMed ID: 9063520
[TBL] [Abstract][Full Text] [Related]
13. Effect of short-term, high-dose retinol on dark adaptation in aging and early age-related maculopathy.
Owsley C; McGwin G; Jackson GR; Heimburger DC; Piyathilake CJ; Klein R; White MF; Kallies K
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1310-8. PubMed ID: 16565362
[TBL] [Abstract][Full Text] [Related]
14. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U
J Clin Oncol; 2001 Mar; 19(6):1664-70. PubMed ID: 11250995
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of the synthetic retinoid Fenretinide (HPR).
Costa A; Malone W; Perloff M; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M; Andreoli C; Del Vecchio M
Eur J Cancer Clin Oncol; 1989 May; 25(5):805-8. PubMed ID: 2525470
[TBL] [Abstract][Full Text] [Related]
16. Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects.
Dimitrov NV; Meyer CJ; Perloff M; Ruppenthal MM; Phillipich MJ; Gilliland D; Malone W; Minn FL
Am J Clin Nutr; 1990 Jun; 51(6):1082-7. PubMed ID: 2140925
[TBL] [Abstract][Full Text] [Related]
17. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of fenretinide (4-HPR) inhibition of β-carotene monooxygenase 1. New suspect for the visual side effects of fenretinide.
Poliakov E; Gubin A; Laird J; Gentleman S; Salomon RG; Redmond TM
Adv Exp Med Biol; 2012; 723():167-74. PubMed ID: 22183330
[No Abstract] [Full Text] [Related]
19. N-(4-hydroxyphenyl)-retinamide increases lecithin:retinol acyltransferase activity in rat liver.
Matsuura T; Zhao Z; Ross AC
J Nutr; 1996 Oct; 126(10):2474-80. PubMed ID: 8857507
[TBL] [Abstract][Full Text] [Related]
20. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.
Formelli F; Clerici M; Campa T; Di Mauro MG; Magni A; Mascotti G; Moglia D; De Palo G; Costa A; Veronesi U
J Clin Oncol; 1993 Oct; 11(10):2036-42. PubMed ID: 8410127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
